Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 3 11Phase 2 7Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 7INDUSTRY 2NIH 1NETWORK 1INDIV 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Sarcoma 2Stomach Neoplasms 1Sarcoma, Ewing 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × PM 01183 × Clear all
NCT05734066 2026-02-03

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Jazz Pharmaceuticals

Phase 1/2 Recruiting
60 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡